Navigation Links
AltheaDx and Compendia Bioscience Launch the Breast Cancer Segregation Panel™
Date:12/8/2010

SAN DIEGO, Dec. 8, 2010 /PRNewswire/ -- AltheaDx, Inc. – http://www.altheadx.com – today announced the formation of a strategic partnership with Compendia Bioscience to combine their respective core capabilities in assay development, validation and bioinformatics. The two companies will jointly create novel products and services focused on cancer biomarker discovery and subsequent development of tests that predict patient outcomes in clinical trials. From 2006, AltheaDx has enabled FFPE tissue-based biomarker discovery and companion diagnostic development. AltheaDx has facilitated the clinical utilization of biomarkers through validation and clinical sample testing under GLP and/or CLIA.

Compendia Bioscience co-founder and CEO, Dan Rhodes said, "AltheaDx has been a pioneering developer of PCR-based assays in clinical settings since its inception with very deep technical capabilities in genetic analysis.  We are thrilled by this new strategic partnership."

The inaugural product launch of the strategic partnership is the Breast Cancer Segregation Panel™ Assay.  This test is a real-time PCR-based panel, optimized for analysis of RNA extracted from formalin-fixed, paraffin-embedded (FFPE) tissues.  This panel measures 96 genes identified in a proprietary meta-analysis of cancer genomic data from more than 5,000 clinical samples.  AltheaDx will process and analyze samples in its San Diego-based CLIA/GLP laboratory while Compendia Bioscience will manage downstream data analysis and statistical correlation to patient outcomes in clinical trials.

"We are excited to announce this new partnership with Compendia Bioscience," said Francois Ferre, AltheaDx's co-founder and CEO.  "Compendia Bioscience is the recognized leader in translating cancer genomic data into meaningful information related to patient outcomes in clinical trials.  Compendia's powerful bioinformatics platform is providing highly valuable content around which we can develop predictive tests for our pharma partners."

Under the terms of the partnership the companies plan to develop Segregation Panels for other cancer types.  The next assay, the Colorectal Cancer Segregation Panel™, will be released in 2011.

About AltheaDx, Inc.AltheaDx, a leading San Diego-based diagnostic development and testing company, provides clinical biomarker discovery, assay development and validation services that support researchers worldwide in their efforts to utilize genomic information for the advancement of novel therapies.  AltheaDx plays a critical role in helping pharma to discover and validate biomarkers that can predict drug response, and then to provide an efficient seamless commercialization path to bring the tests to market.  The goal of AltheaDx is to reduce the time, risk, and cost of therapeutic development for pharma partners.

For more information, visit www.altheadx.com

About Compendia Bioscience, Inc.Compendia Bioscience is dedicated to applying the global collection of cancer genomic data to impact patient treatment by enabling the discovery and development of better cancer diagnostics and treatments. www.compendiabio.comFor additional information please contact: Matt Gorovoy, PhDAssociate Director, Corporate DevelopmentAltheaDx, Inc.Phone: 858-882-0123 ext. 489E-mail: mgorovoy@altheadx.com
'/>"/>

SOURCE AltheaDx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. On Third Anniversary, Compendia Bioscience Announces Continued Revenue Growth, Major Long-Term Customer Contracts and Forecasts Profitability
2. Compendia Bioscience Announces the Release of Oncomine 4 Research Edition
3. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
4. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
5. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
6. Milestone Biosciences, LLC Further Strengthens Executive Management Team
7. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
8. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
9. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
10. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
11. Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 24, 2017  Aethlon Medical, Inc. (Nasdaq: ... authored by its Chairman and CEO, Jim Joyce ... Munich Security Conference last Saturday, Bill Gates ... kill more people than nuclear weapons. Mr. Gates expressed ... U.K. intelligence agencies, that scientific terrorists have access to ...
(Date:2/24/2017)... , Feb. 24, 2017  Driven by consumers, ... are now the fastest growing categories, finds the ... Actives in Personal Care: Multi-regional Market Analysis and ... management consulting firm Kline. "Biotechnology actives ... make them more effective for skin and hair ...
(Date:2/24/2017)... ... February 24, 2017 , ... FireflySci, Inc is an explosive ... 2014, FireflySci had the goal of bringing their powerful cuvette and spectrophotometer ... the path that FireflySci is going on as they add yet another mark on ...
(Date:2/24/2017)... Feb. 24, 2017  VWR Corporation (NASDAQ: VWR), the leading ... and production customers, today reported its financial results for the ... Highlights: 4Q16 record quarterly net ... on an organic basis. 4Q16 ... organic basis, while the Americas net sales increased 2.5%, or ...
Breaking Biology Technology:
(Date:2/9/2017)... 2017 The biomass boiler market report by ... boiler market globally in terms of revenue (US$ Mn) ... market for biomass boilers has been segmented on the ... country/region. The market based on feedstock type, has been ... & energy crops, urban residues, and others. On the ...
(Date:2/8/2017)... 2017 The biometrics market has reached ... of organizations, desires to better authenticate or identify ... and challenge questions), biometrics is quickly working its ... market is driven by use cases, though there ... enterprise uses cases, with consumer-facing use cases encompassing ...
(Date:2/7/2017)... , February 7, 2017 ... Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") ... electronic transaction processing services, is pleased to announce the ... Company. Effective January 31, 2017, Philip ... of Directors, CEO and President.  An experienced payment industry ...
Breaking Biology News(10 mins):